Values and correlations between C-reactive protein and apolipoprotein B after treatment with methotrexate at patients with rheumatoid arthritis

Basit Öğe Kaydı
dc.authorscopusid57194635496
dc.authorscopusid57209322880
dc.authorscopusid57194631935
dc.contributor.authorIsmaili H.
dc.contributor.authorIsmaili L.
dc.contributor.authorRexhepi M.
dc.date.accessioned2024-06-12T10:26:10Z
dc.date.available2024-06-12T10:26:10Z
dc.date.issued2019
dc.description.abstractBACKGROUND: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Lipid changes related to inflammation have been described in RA. Methotrexate (MTX) treatment is effective in controlling inflammation and decreasing the CRP (C-reactive protein) values. AIM: To examine the disease activity, CRP and Apo B values in the detection of new patients with active and untreated RA, and impact of MTX therapy on their levels after 6 months and one year of treatment, and the correlation between their values in this period. METHODS: 80 patients with active and newly discovered RA patients who meet the American Rheumatology Association (ARA) 1987 revised criteria were treated with disease-modifying anti-inflammatory drugs (DMARDs) according to the protocol for treatment. RESULTS: After a year of therapy RA patients achieved significant decrease in the DAS28 (disease activity score) (p < 0.01 and p < 0.001), and CRP values (p < 0.001). Levels of Apo B values at the 12 months were nonsignificantly higher compared to the results obtained at the beginning of the study (p < 0.001). After 6 and 12 months there was a weak nonsignificant negative correlation about the values of CRP and Apo B at baseline and after 12 months (r = –0.15 and r =-0.12 p > 0.05). CONCLUSION: Use of MTX therapy at RA patients had a reduced effect on disease activity and inflammation, but the nonsignificance effect on the values of Apo B lipoproteins. © 2019 Hysni Ismaili, Levent Ismaili, Meral Rexhepi.en_US
dc.identifier.doi10.3889/oamjms.2019.278
dc.identifier.endpage1298en_US
dc.identifier.issn1857-9655
dc.identifier.issue8en_US
dc.identifier.scopus2-s2.0-85067339226en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1293en_US
dc.identifier.urihttps://doi.org/10.3889/oamjms.2019.278
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16678
dc.identifier.volume7en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherOpen Access Macedonian Journal of Medical Sciencesen_US
dc.relation.ispartofOpen Access Macedonian Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectApolipoprotein B (Apo B); C-Reactive Protein (Crp); Methotrexate (Mtx); Rheumatoid Arthritis (Ra)en_US
dc.subjectApolipoprotein B; C Reactive Protein; Disease Modifying Antirheumatic Drug; Methotrexate; Rheumatoid Factor; Adult; Article; Body Mass; Cardiovascular Disease; Cardiovascular Risk; Das28; Disease Activity; Disease Activity Score; Disease Duration; Erythrocyte Sedimentation Rate; Female; Follow Up; Human; Inflammation; Joint Swelling; Major Clinical Study; Male; Middle Aged; Morning Stiffness; Questionnaire; Rheumatoid Arthritis; Visual Analog Scaleen_US
dc.titleValues and correlations between C-reactive protein and apolipoprotein B after treatment with methotrexate at patients with rheumatoid arthritisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu